Biosimilars LatAm – Colombia 2024

The 2024 edition in Colombia focuses on facilitating local biosimilar production through the exploration of external expertise and successful industry practices. This forum serves as a platform for professionals to engage in strategic discussions aimed at advancing biosimilar development in the region.


La edición 2024 en Colombia se centra en facilitar la producción local de biosimilares mediante la exploración de la experiencia de expertos externos y prácticas exitosas de la industria. Este foro sirve como plataforma para que los profesionales participen en discusiones estratégicas destinadas a avanzar en el desarrollo de biosimilares en la región.

Who will
you meet?


More than:









Service Providers

Government Agencies

Industry Executives from Latam

From these areas:

  • Biosimilars
  • Biobetters
  • Biotechnology
  • Biotherapeutics
  • Analytical science
  • Regulatory compliance
  • Quality Control
  • Clinical immunology
  • Scientific Affairs
  • Pharmacovigilance
  • Research
  • Regulatory
  • Business Development
  • Marketing

Plan Your 1-to-1 Meetings with JackLeckerman App

1. JackLeckerman App: Login & Meeting Notifications

Download the JackLeckerman App and sign up.

Check your email for the login details, or use the “Forgot Password” option to retrieve them.

You will receive meeting reminders on your mobile.

These reminders will include meeting requests, meeting confirmations, and messages from other attendees and the coordinator.

2. Attendee list to Plan Your Meetings

Browse the attendee list and select someone for a 10-minute 1-to-1 Meeting request.

Meeting requests close one hour before each Networking session in the program.

3. Managing Meeting Requests, Your Meetings Schedule

Accept or decline meeting requests through the “Meetings” button.

Check your scheduled meetings for the upcoming networking break.

4. Meeting Point Location in the Coffee Break Area

Go to the coffee break area and find the table number to meet your colleague

Speaker Board 

Program at a Glance

Regulatory Updates in Colombia
Best Practices in Biosimilar Public Procurement

There is a significant discussion about public procurement based more on value than price to ensure product supply, including the debate on multiple awards versus the winner takes all principle, currently seen in Europe. The model based on European regulation for tender evaluation, “Most Economically Advantageous Tender,” incorporates other variables beyond price into the decision algorithm. In the current state of biosimilar development, a multifactorial value proposition is crucial.

Challenges and Strategies for Local Biosimilar Development and Production Initiatives

Colombia faces a significant gap in local biosimilar production, highlighting the country’s dependency on imported biologic drugs. However, promising initiatives are emerging. The INC and IDCBIS, among other organizations, is spearheading efforts to establish local manufacturing capabilities. This strategic move aims to enhance accessibility to crucial biologic treatments, potentially reshaping Colombia’s pharmaceutical landscape.

Key Note: Unveiling the Keys to Local Production in LatAm

The significance of local biosimilar production cannot be overstated in ensuring a nation’s healthcare autonomy. While the journey towards achieving this goal may seem daunting, success stories from countries like Brazil, Mexico, and Argentina prove it is attainable in Latin America. These nations not only manufacture biosimilars domestically but also export them, significantly enhancing access to vital therapies domestically and abroad. To propel Colombia’s industry forward, analysing these case studies is imperative. By understanding the challenges, support systems, and societal benefits these countries have experienced, Colombia can pave the way for a thriving local biosimilar industry.

COFEPRIS Certainty Strategy Implementation

In Mexico, COFEPRIS is currently undertaking a strategic initiative to provide regulatory certainty to pharmaceutical companies, enabling them to introduce medical innovations and drive productive development in the Mexican market. The 2022−2030 agenda aims to foster competitiveness, industrial and commercial growth, and ensure access to safe and high-quality healthcare products. The implementation of this strategy focuses on harmonising regulatory approaches with other agencies, involving the public, private and social sectors, and compliance with ICH guidelines, among other factors. The success of this initiative will play a crucial role in fostering the widespread adoption of biosimilars throughout Latin America.

Regulatory Policy Priorities that International Companies Consider for Technology Transfer Agreements

In the realm of technology transfer agreements within the biosimilars sector (such as Brazil’s PDPs), international companies place significant emphasis on regulatory policies. These policies play a crucial role in ensuring compliance with local standards and requirements. Firms navigating this landscape aim to strike a delicate balance between fostering innovation and meeting stringent regulatory demands. Through strategic partnerships that align with local manufacturing policies, the focus remains on safeguarding the quality, affordability, and accessibility of biosimilar therapies, thereby contributing to the advancement of healthcare accessibility and affordability.

Cuban Regulatory Expertise for the Colombian Market: Biologics Case Studies

Exploring the achievements of the Cuban Regulatory Agency unveils valuable lessons for Colombia’s nascent biosimilar industry. This investigation illuminates Cuba’s successful regulatory strategies, showcasing their potential applicability to Colombia’s evolving biologics landscape. From efficient approval processes to the promotion of local manufacturing, these insights offer a roadmap for Colombia’s biosimilar sector to thrive and improve healthcare accessibility.

Full Programme in the PDF Agenda

Download Agenda



Cytiva is a global provider of technologies and services that help advance and accelerate the development and production of therapeutic products. Promoting training, speed and efficiency for research and production workflows, allowing the delivery of innovative medicines to patients.


With 70+ dedicated scientists and supporting personnel, we are a third-party laboratory authorized by the Mexican Regulatory Agency (COFEPRIS) to conduct analytical services of pharmaceutical products and medical devices, as well as biosimilarity assessment of biotechnological products to be registered in Mexico. We also provide products, solutions and consulting services on antibody engineering and development of antibody-based therapeutics. Our capabilities allow us offering services throughout different development stages, from bench to non-clinical assessment. Our ALTHEA Libraries™ platform has served us to develop a portfolio of innovative antibodies and also to provide discovery services to companies in Mexico and USA


The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2019, the company earned sales revenue of some 1.83 billion euros according to preliminary figures. At the end of 2019, more than 9,000 people work at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.


As Part of Terumo Medical Care Solutions, the Pharmaceutical Solutions Division develops patient-oriented parenteral delivery solutions for therapeutic performance and safety.

Globally trusted for quality and precision, we offer pharmaceutical and medical device manufacturers around the world comprehensive product design and development services.

We have decades of experience collaborating with pharmaceutical companies from the earliest phases of drug development to product commercialization to optimize critical aspects of parenteral drug delivery.

Innovation and creativity are central to our value proposition. Our expert teams lead the industry in developing and manufacturing advanced, high-performing infusion and injection technologies, including CDMO services for all parenteral applications.

We listen. We question. We deliver. 

Photo Gallery from Previous Events


Previous Forums

Keep me updated